New study checks if etrasimod passes into breast milk
NCT ID NCT07153159
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing how much of the drug etrasimod ends up in breast milk. Eight healthy breastfeeding women will take a 2 mg pill daily for a week while staying at a clinic. They will not breastfeed their babies during the study to keep them safe. Researchers will measure drug levels in blood and milk to understand how much passes through.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Etrasimod (oral tablet, 2 mg once daily for 7 days)
What this could lead to
If successful, this study will provide crucial data on how much etrasimod enters breast milk, helping doctors advise breastfeeding women about its safety.
What could go wrong
This is a very small, early-phase study in healthy women, not patients. It only measures drug levels, not health outcomes, so it cannot prove safety or effectiveness for any condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pfizer Clinical Research Unit - Brussels
RECRUITINGBrussels, Bruxelles-capitale, Région de, B-1070, Belgium